About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company's lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company's earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: INSM
- Previous Close: $14.39
- 50 Day Moving Average: $15.01
- 200 Day Moving Average: $13.93
- 52-Week Range: $61,955,000.00 - $9.02
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.61
- P/E Growth: 0.00
- Market Cap: $891.53M
- Outstanding Shares: 61,955,000
- Beta: 0.67
- Return on Equity: -52.37%
- Return on Assets: -44.14%
Companies Related to Insmed Incorporated:
- Debt-to-Equity Ratio: 0.16%
- Current Ratio: 8.80%
- Quick Ratio: 8.80%
What is Insmed Incorporated's stock symbol?
Insmed Incorporated trades on the NASDAQ under the ticker symbol "INSM."
Where is Insmed Incorporated's stock going? Where will Insmed Incorporated's stock price be in 2017?
6 analysts have issued twelve-month price objectives for Insmed Incorporated's shares. Their predictions range from $13.00 to $24.00. On average, they anticipate Insmed Incorporated's stock price to reach $20.75 in the next year.
When will Insmed Incorporated announce their earnings?
Insmed Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
Who owns Insmed Incorporated stock?
Insmed Incorporated's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Palo Alto Investors LLC (8.80%), Patrick Lee, MD (8.80%), Orbimed Advisors LLC (8.57%), Janus Capital Management LLC (4.61%) and State Street Corp (2.31%). Company insiders that own Insmed Incorporated stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden, Jr, Mark Quigley, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis.
Who sold Insmed Incorporated stock? Who is selling Insmed Incorporated stock?
Insmed Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Janus Capital Management LLC, Frontier Wealth Management LLC and Tudor Investment Corp Et Al. Company insiders that have sold Insmed Incorporated stock in the last year include Andrew T Drechsler, Myrtle S Potter and Orlov S Nicole Schaeffer.
Who bought Insmed Incorporated stock? Who is buying Insmed Incorporated stock?
Insmed Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Paulson & CO. Inc., Alyeska Investment Group L.P., Orbimed Advisors LLC, Denver Investment Advisors LLC, Russell Investments Group Ltd., State Street Corp and Trexquant Investment LP. Company insiders that have bought Insmed Incorporated stock in the last two years include Christine A Pellizzari and William Lewis.
How do I buy Insmed Incorporated stock?
Shares of Insmed Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Insmed Incorporated stock cost?
One share of Insmed Incorporated stock can currently be purchased for approximately $14.39.